Prevalence of contrast nephropathy following the administration of N-acetyl cysteine; a systematic review and meta-analysis

Marzieh Khosravani Moghadam, Hamid Nasri

1 Isfahan University of Medical Sciences, Isfahan, Iran
2 Nickan Research Institute, Isfahan, Iran

Correspondence to: Prof. Hamid Nasri, Email: hamidnasri@yahoo.com, hamidnasri@med.mui.ac.ir

Received: 2 Apr. 2021
Accepted: 31 May 2021
ePublished: 10 May 2021

Keywords: N-acetyl cysteine, Acute kidney injury, Nephrotoxicity, Contrast media, Contrast-induced AKI, Contrast nephropathy

Abstract

Introduction: Nephropathy is a serious complication in patients receiving contrast during imaging. N-acetyl cysteine (NAC) can reduce the contrast nephropathy. This review evaluates the prevalence of contrast-induced nephropathy (CIN) following the administration of NAC.

Methods: A systematic literature search and meta-analysis was conducted in Scopus, Web of Science and PubMed for articles published by December 30, 2019 including the keywords of “N-acetyl cysteine”, “Acute kidney injury”, “Nephrotoxicity”, “Contrast media”, “Contrast-induced AKI” and “Contrast nephropathy”.

Results: A total of 29 articles of 537 studies examining 5,980 individuals were incorporated in this systematic review and meta-analysis. Pooled estimation of a meta-analysis of prevalence studies reported a prevalence of 9% (0.09), i.e. nine out of every 100 patients undergoing contrast media resulted in CIN but a prevalence of 14% (0.14) was observed in the placebo group. In addition, 41 out of every 100 patients with hypertension undergoing contrast media resulted in CIN (prevalence: 41%) and 64 out of every 100 patients with diabetes undergoing contrast media resulted in CIN (prevalence: 64%).

Conclusion: The prevalence of CIN in the group receiving NAC is lower than those who did not receive this drug. Additionally, in patients suffering from diabetes and hypertension, CIN is more prevalent compared to healthy people.

Introduction

The use of contrast agents in imaging exposes the kidneys to damage, which is called contrast-induced nephropathy (CIN). The term is used when serum creatinine more than 25% of baseline or more than 0.5 mg/dL increases within 2-3 days after contrast administration, without the presence of other kidney diseases. The incidence of CIN in the adult population undergoing cardiac angiography is about 30% (1). Occurrence of CIN is of great importance because of its high mortality rate that is reported to be as high as 34% (2). Contrast agents are one of the most important causes of damage to renal tubules and acute tubular necrosis. Risk factors for nephropathy due to contrast agents include diabetes, chronic renal failure, severe congestive heart failure, fluid loss, hypotension, type and volume of contrast medium (3). Nephropathy due to contrast agents is the third most common cause of acute renal failure followed by low blood pressure and surgery in the hospital (4). People with a history of kidney failure, especially kidney damage due to diabetes, congestive heart failure, low blood pressure, high levels of contrast agents and concomitant use of drugs that impair kidney function, are at higher risk (5). Various substances have been tested in various studies to prevent harmful effects of contrast agents on the kidney including N-acetyl cysteine (NAC), theophylline, sodium bicarbonate, ascorbic acid, and diuretics (6). There are some meta-analyses regarding the effectiveness of NAC to prevent CIN. For example, a study by Sharp et al in 2019 (7), but another meta-analysis conducted by Li et al in 2017 showed that NAC therapy is not effective to prevent CIN in patients following angioplasty as a preventative treatment (8).
Methods
This systematic review and meta-analysis was designed based on the Preferred Reporting Items for Systematic Reviews and Meta-analysis guidelines (9).

Search strategy
Scopus, Web of Science, and PubMed were considered for papers published by December 30, 2019. The keywords searched were “N-acetyl cysteine”, “Acute kidney injury”, “Nephrotoxicity”, “Contrast media”, “Contrast-induced AKI” and “Contrast nephropathy” or a combination of them in the titles or abstracts. The references of the published articles were manually reviewed for additional relevant articles. The duplicate studies were removed by EndNote. The search strategy for PubMed is a sample of syntax done for this review.

((N-Acetyl Cysteine [Title/Abstract] OR NAC [Title/Abstract]) AND ((acute kidney injury [MeSH Terms] OR acute kidney injury [Title/Abstract] OR AKI [Title/Abstract] OR kidney injury [Title/Abstract] OR nephropathy [Title/Abstract] OR acute tubular necrosis [Title/Abstract] OR renal injury [Title/Abstract]) AND ((Contrast media [MeSH Terms] OR Contrast media [Title/Abstract] OR Contrast-induced [Title/Abstract] OR Contrast nephropathy [Title/Abstract])))

Eligibility criteria
Two of the authors independently evaluated the eligibility of the papers according to the PRISMA guidelines. Inclusion criteria were studies in English about nephropathy after contrast medium receiving in patients who received NAC as intervention in original studies, case series or case reports, but only original and case series were added in the meta-analysis. Exclusion criteria were studies done on animals.

Data extraction
A structured checklist was used for the data extraction including, type of study, patients numbers, age, nephropathy (number, %), comorbidity, gender, NAC dose and complications. The data were retrieved by two independent investigators. The differences observed in this process were corrected by a third investigator independent from the other two. The Newcastle Ottawa Quality Assessment Scale (NOS) was used for qualitative assessment of studies (10).

Statistical analysis
The main measure of effect/effect size was prevalence (ratio of case to total population). Cochran’s test (Q-test) (showing significant heterogeneity in the meta-analysis) and I2 (showing the amount of heterogeneity ranged from 0% to 100 %.) were used to assess the heterogeneity among the studies. The random-effects model was used for the continuous and frequency outcome under study. Additionally, a random effects meta-analysis was applied for estimating the main index, which was the pooled prevalence, at 95% confidence interval. A forest plot was used to present the pooled prevalence. Publication bias was assessed using Begg’s tests. The analysis was performed using Stats version 13.

Results
A total of 29 articles of 537 studies examining 5980 patients were included in this systematic review and meta-analysis (Figure 1). Study characteristics of the patients included in the meta-analysis are presented in Table 1.

| Records identified through database searching (n = 537) |
|------------------------------------------------------|
| Records after duplicates removed (n = 271) |
| Records screened (n = 130) |
| Records excluded (n = 101) |
| Full-text articles assessed for eligibility (n = 29) |
| Excluded articles (n = 101) |
| Animal articles (n = 38) |
| Other reasons (n = 63) |
| Studies included in qualitative synthesis (n = 29) |

Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analysis flowchart.
N-acetyl cysteine in CIN

Table 1. Study characteristics of the patients included in the meta-analysis

| Author                  | Design | Sample size | Age (year) | Gender | NAC dose (mg) | Duration of use (day) | CIN | Cr (mg/dL) | BUN (mg/dL) | GFR (mL/min) | Comorbidity                                                                 | Case                                | Contrast (dose)                                                                 |
|-------------------------|--------|-------------|------------|--------|---------------|-----------------------|-----|-------------|--------------|--------------|-----------------------------------------------------------------------------|-------------------------------------|--------------------------------------------------------------------------------|
| Ala et al (11)          | RCT    | 100 In: 50  | Co: 50     | 50-59  | F:48 M:52     | 600 twice daily       | 2   | In: 11 Co:19| 0.828        | 16.1         | 98.04 Diabetes: 5                                                            | Coronary artery angiography         | Meglumine Compound 76% (120 ml)                                             |
| Vallero et al (12)      | RCT    | 100 In: 50  | Co: 50     | -      | -             | 600 twice daily       | 2   | In: 6 Co:9 | 1.2          | -            | - Coronary angiography and/or transluminal angioplasty                      | -                                   | Iodixanol; Visipaque 320, Nycomed (203 mL/procedure)                         |
| Hoffmann et al (13)     | Cohort | 50          | 32.8       | F:26 M:24| 600 twice daily| 2               | -   | 0.82        | 29.8         | 106          | - Coronary artery angiography                                               | -                                   |                                                                                  |
| Oldemeyer et al (14)    | RCT    | 96 In: 49   | Co: 47     | In: 77 | Co:74         | F:22 M:27            | 1500| 10000       | 1.63         | 34.4         | Diabetes: 5 Myocardial infarction: 6 Coronary revascularization: 10 Heart failure: 14 Hypercholesterolemia: 20 | Coronary artery angiography         | 134 ml/ Gastrointestinal complication in 16% of receiving NAC               |
| Balderramo et al (15)   | RCT    | 61 In: 33   | Co: 28     | -      | -             | 1200 mg orally 3 h before and 1 after the procedure | 1   | In: 1 Co:2 | -            | -            | -                                                                          | -                                   |                                                                                  |
| Fung et al (16)         | RCT    | 91 In: 46   | Co: 45     | F:17 M:64| 400 mg, thrice daily | 1               | In: 6 Co:8 | In: 2.27 Co: 2.4 | -            | -            | Nephrosclerosis:20 Diabetes:23                                                | Elective coronary angiography       | Nonionic low-osmolality contrast iopromide                                    |
| Hobiskoğlu et al (17)   | RCT    | 81 In: 40   | Co: 41     | 62     | F:23 M:58     | 600 mg NAC before 3 h and after 6 h | 1   | In: 2 Co:4 | -            | -            | -                                                                          | -                                   |                                                                                   |
| Durham et al (18)       | RCT    | 79 In: 39   | Co: 40     | In: 69 | Co:79.4      | 1200 mg NAC before 1 hr. and after 3 h | 1   | In: 3 Co:5 | -            | -            | Diabetes:24                                                                  | Cardiac angiography                 | Omnipaque                                                                      |
| Allaqaband et al (16)   | RCT    | 123 In: 45  | Co: 78     | 71     | F:52 M:71     | 600 mg twice daily    | 1   | In:15 Co:13| 2.03         | -            | -                                                                          | Diabetes:38 CHF-A3                  | Low-osmolality nonionic contrast/1.54 mL/kg                                 |
| Hsu et al (19)          | RCT    | 20          | -          | -      | 600 mg orally twice a day | -               | In: 0 Co:5 | -            | 24.5         | -            | -                                                                          | -                                   | Omnipaque (iobexol)                                                            |
Table 1. Continued

| Author           | Design      | Sample size       | Age (year) | Gender | NAC dose (mg) | Duration of use (day) | CIN | Cr (mg/dL) | BUN (mg/dL) | GFR (ml/min) | Comorbidity              | Case                      | Contrast (dose)            |
|------------------|-------------|-------------------|------------|--------|---------------|------------------------|-----|-------------|-------------|--------------|--------------------------|---------------------------|-----------------------------|
| Ozcan et al      | RCT         | 264, Three groups of 88 | 69         | F:67   | 600 mg orally twice a day | 2 | Sodium bicarbonate: 6 Sodium chloride:16, NAC:15 | -  | -           | 45.3 (Creatinine clearance) | Diabetes:52 CHF:33       | Cardiac angiography        | 110 ml of ioxaglate       |
| Shavit et al     | Retrospective | 140              | -          | -      | -             | -                      | In: 6 | Co:11      | -            | -            | -                        | Cardiac catheterization    | -                           |
| Negita et al     | Retrospective | 168              | -          | -      | -             | -                      | In: 3 | Co:15      | -            | -            | -                        | Cardiac catheterization    | -                           |
| Amini et al      | RCT         | 87                | In: 63.25  | Co:65.09 | F:36 M: 54    | -                      | In:5 | Co:6       | -            | -            | -                        | Elective diagnostic coronary angiography | Iohexol (100 mL) and iodoxanol (6 mL) |
| Jo et al         | RCT         | 212               | In: 64.3   | Co:65.6 | F:47 M: 165   | 1200 mg orally twice a day | In:2 | Co:5       | 1.41         | -            | -                        | Diabetes: 43               | Cardiac catheterization    | Iodoxanol                |
| Buyukhatipoglu et al | RCT         | 60                | In:58.9    | Co:61.8 | F:18 M: 42    | 600 mg NAC intravenously | 2   | In: 1       | 1            | 42.3         | -                        | Cardiac catheterization    | -                           |
| Calabro et al    | RCT         | 597               | In: 342    | Co:255 | >65           | 600 mg before and after | 1   | In: 15      | -            | -            | -                        | Coronary artery angiography | -                           |
| Kinbara et al    | RCT         | 45                | In: 15     | Co:35   | 704 mg orally twice daily | 2   | 0           | 0.67         | -            | 46.1 (Creatinine clearance) | Diabetes: 43 Hypertension: 13 | Coronary artery angiography | 147 ml                   |
| Calabro et al    | RCT         | 322               | In: 152    | Co:170 | 54            | -                      | In: 4 | Co:19      | -            | -            | -                        | -                         | -                           |
| Chong et al      | RCT         | 548               | In: 185    | Co:182  | 1.2 g BID     | 3 | In: 4        | 134 µmol/L   | 48.3 (Creatinine clearance) | -                        | Elective cardiac catheterisation | Iohexol, iopamidol, ioversol and iopromide | -                           |
| Author                  | Design | Sample size | Age (year) | Gender | NAC dose (mg) | Duration of use (day) | CIN | Cr (mg/dL) | BUN (mg/dL) | GFR (ml/min) | Comorbidity                          | Case                                      | Contrast (dose) |
|-------------------------|--------|-------------|------------|--------|---------------|-----------------------|-----|------------|-------------|-------------|-------------------------------------|------------------------------------------|----------------|
| Aslanger et al (30)     | RCT    | 312 In : 104 Co 1:104 Con2:104 | 56         | F:112 M: 241 | 1200 mg orally twice a day | 2                      | In: 27 Co1:24 Con2:23 | 0.9           | -            | 107                                      | Diabetes: 27 Hypertension: 55           | Low-osmolality contrast agent, ioxaglate |
| Hsu et al (31)          | RCT    | 209 In: 106 Co:103 | 79.6       | F:106 M: 103 | 600 mg intravenously | 1                      | In: 7 Co:14 | 1.4         | -            | 36.7 (Creatinine clearance)         | Diabetes: 31 Hypertension: 70 Chronic kidney disease: 32 | Iobitridol, Iohexol and iopromide         |
| Jaffery et al (32)      | RCT    | 398 In: 206 Co:192 | 65.4       | F:252 M: 146 | 1200 mg bolus followed by 200 mg/h for 24 h | 1                      | In: 33 Co:25 | 1.09       | -            | 87.4 (Creatinine clearance)         | Diabetes: 73 Hypertension: 152           | Iodoxanol                                   |
| Albabtain et al (33)    | RCT    | 243 In: 62 Co1:57 Co2:58 | 61.1       | F:66 M: 177 | 600 mg twice daily | 2                      | In: 11 Co1:7 Co2:10 | 1.48       | -            | 61.5 (Creatinine clearance)         | Diabetes: 52 Hypertension: 38           | Elective cardiac catheterisation         |
| Alessandri et al (34)   | RCT    | 296 In: 118 Co:158 | 65         | F:97 M: 199 | 1200 mg daily   | 2                      | In: 7 Co:8 | -           | -            | -           |                                    |                                         |                                   |
| Alioglu et al (35)      | RCT    | 113 In: 49 Co:64 | -          | In: 62.73 Co:60.84 | 600 mg twice a day | 2                      | In: 6 Co:11 | 0.99       | -            | 78.31                               | Diabetes: 11 Elective cardiac catheterisation | Iomeron                                |
| Heguilen et al (36)     | RCT    | 123 In: 81 Co:42 | -          | -          | 1200 mg daily   | 2                      | In: 9 Co:15 | -           | -            | -          |                                    | Elective cardiac catheterisation         | Ioxaglate                           |
| Thayssen et al (337)    | RCT    | 715 In:176 Con: 539 | 65         | F:165 M: 550 | 600 mg BID      | 2                      | In: 32 Co109 | 0.84       | -            | 94.3                               | Diabetes: 15 Hypertension: 58 Angiography and coronary revascularisation | Visipaque, omnipaque                     |
| Habib et al (38)        | RCT    | 105 In: 30 Co:75 | 62.3       | F:44 M: 61 | 1200 mg orally BID | 2                      | In: 2 Co:13 | 0.96       | -            | -          |                                    |                                         |                                   |
| Biernacka-Fialkowski et al (39) | RCT | 222 In: 108 Co:114 | In: 66 Co:64.3 | F:53 M: 171 | 600 mg intravenously | 1                      | In: 9 Co:21 | -           | -            | 76.2                               | Diabetes: 34 Hypertension: 98           |                                         |
**Descriptive characteristics**
The mean age of the participated individuals was 63.57 ± 9.18 years. The mean serum creatinine, BUN and creatinine clearance and additionally glomerular filtration rate (GFR) levels in the patients undergoing contrast media were 1.23 mg/dL, 30.65 mg/dL, 45.10 mL/min and 93.30 ml/min (Table 2). Regarding the dose of NAC administered in the prevention of CIN, the most common dose was 600 mg twice daily by two days (Figure 2).

**Prevalence of CIN in the intervention groups**
Pooled estimation of a meta-analysis of prevalence studies reported a prevalence of 9% (0.09), i.e. nine out of every 100 patients undergoing contrast media with NAC resulted in CIN (Figure 3).

**Prevalence of CIN in the placebo groups**
Pooled estimation of a meta-analysis of prevalence studies reported a prevalence of 14% (0.14), i.e. 14 out of every 100 patients undergoing contrast media without NAC resulted in CIN (Figure 4).

**Prevalence of diabetes in the patients who developed CIN**
Pooled estimation of a meta-analysis of prevalence studies reported a prevalence of 64% (0.64), i.e. 64 out of every 100 patients with diabetes undergoing contrast media resulted in CIN (Figure 5).

**Prevalence of hypertension in the patients who developed CIN**
Pooled estimation of a meta-analysis of prevalence studies reported a prevalence of 41% (0.41), i.e. 41 out of every 100 patients with hypertension undergoing contrast media resulted in CIN (Figure 6).

**Publication bias**
The results of the analysis showed that bias publication did not have an influence on the creation of negative results, which is shown as symmetry in the funnel plot. Meanwhile, no evidence of publication bias was detected using Egger’s test (Egger’s test t = 2.84, P = 0.014, 95% CI: 2.207 to 16.206).

**Table 2.** Descriptive characteristics of the individuals who underwent contract media

| Variable                        | Minimum | Maximum | Mean   | SD    |
|---------------------------------|---------|---------|--------|-------|
| Age (y)                         | 32.80   | 79.60   | 63.573 | 9.189 |
| Creatinine (mg/dL)              | 0.67    | 2.27    | 1.239  | 0.448 |
| BUN (mg/dL)                     | 16.10   | 42.30   | 30.650 | 10.988|
| Creatinine clearance (mL/min)   | 24.50   | 87.40   | 45.100 | 18.257|
| GFR* (ml/min)                   | 76.20   | 107.00  | 93.083 | 13.318|

GFR, glomerular filtration rate.

![Figure 2. NAC used doses according to reports of studies.](image_url)

![Figure 3. Forest plot showing the prevalence of CIN following NAC administration.](image_url)
Discussion

This review showed that the prevalence of CIN in the group receiving NAC is lower than those did not receive NAC (placebo). In addition, CIN in the patients suffering from diabetes (64%) and hypertension (41%) is prevalent compared to healthy people. In a study by Ala et al, investigated the effects of N-acetylcysteine in preventing CIN due to coronary angiography in patients with normal renal function. They showed in the first group, fluids with oral NAC 600 mg twice daily for 2 days (the day before and the day of administration of contrast agent) and in the second group (control group), only fluids were prescribed. CIN was observed in 30 patients, 11 patients (22%) in the NAC group and 19 patients (38%) in the control group, and there was no significant difference. In the control group, the mean serum creatinine of patients increased significantly after 48 hours, but in the NAC group, no significant increase was observed in the mean serum creatinine of patients. These results suggest that AC has been able to reduce contrast-induced renal impairment (11). In a study conducted by Vallero et al in 2002 in Italy on 100 patients undergoing angiography with an iodixanol with a volume of 203 ml from 1-2 hours before to 24 hours after angiography and the NAC group received 600 mg twice daily before and immediately after angiography. Vallero et al showed no potential advantage of NAC in the prevention of acute nephropathy, induced by high volumes of contrast agent (12). The study by Hoffmann et al conducted on 50 patients with healthy renal function under contrast-enhanced angiography. In their investigation, serum creatinine was measured 48 hours after angiography, which showed a significant decrease in the group that received NAC. This study confirmed the effect of NAC in preventing renal impairment of contrast agents in patients with healthy renal function undergoing angiography (14). There is strong controversy about the effectiveness of the NAC. In this regard, Loomba et al showed that NAC may not have any significant effect on clinical outcomes after cardiac catheterization (40). According to the results of a meta-analysis performed by Ali-Hassan-Sayegh et al in 2017, many procedures can be considered to prevent CIN in the patients undergoing angiography such as enough hydration, use of NAC and ascorbic acid (41). Our review approved the effect of NAC in preventing CIN compared to the placebo group in which in patients receiving NAC, the prevalence of CIN was 9% while it was 14% in the control groups. It should be noted that comorbidities can affect the prevalence of CIN, which our review indicated more frequency of hypertension and diabetes among patients with CIN. We showed, 41 out of every 100 patients with hypertension undergoing contrast media resulted in CIN (prevalence: 41%) and 64 out of every 100 patients with diabetes undergoing contrast media resulted in CIN (prevalence: 64%). These values are threatening the life of patients and it is recommended...
to perform larger randomized clinical trials with different groups to find better prophylactic treatment.

Conclusion
The prevalence of CIN in the group receiving NAC is lower than those did not receive NAC (placebo). In addition, CIN in the patients suffering from diabetes (64%) and hypertension (41%) is prevalent compared to healthy people

Authors' contribution
Primary draft by MKM and HN. First edit by HN. Manuscript finalized by MKM and HN both equally. All authors read and signed the final paper.

Conflicts of interest
The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Ethical issues
This study was approved by ethic committee of Isfahan University of Medical Sciences (#IR.MUI.MED.REC.1399.693) and was extracted from the medical thesis of Marzieh Khosravani Moghadam at this university (Thesis #399660). Additionally, ethical issues (including plagiarism, data fabrication, double publication) have been completely observed by the authors.

Funding/Support
None.

References
1. Bartorelli AL, Marenzi G. Contrast-induced nephropathy. J Interv Cardiol. 2008;21:74-85. doi: 10.111/j.1540-8183.2007.00318.x.
2. Levy EM, Viscoli CM, Horwitz RI. The effect of acute renal failure on mortality. A cohort analysis. JAMA, 1996; 275:1489-94.
3. Parfrey PS, Griffiths SM, Barrett BJ. Contrast material-induced renal failure in patients with diabetes mellitus, renal insufficiency, or both: a prospective controlled study. Neg J Med 1989; 320: 143-149. doi: 10.1056/NEJM198901193003003.
4. Tepel M, Acetylcysteine for the prevention of radiocontrast-induced nephropathy, Minerva Cardioangiol 2003;51:525-530.
5. Goldenberg I, Schechter M, Matetzki S. Oral acetylcysteine as an adjunct to saline hydration for prevention of contrast-induced nephropathy following coronary angiography. Eur Heart J 2004;25:212-8. doi: 10.1016/j.ehj.2003.11.011.
6. Allaqaband S, Tumuluri R, Malik A. Prospective randomized study of Nacetylcystein, fenoldopam, and saline for prevention of radiocontrast-induced nephropathy. Catheter Cardiovasc Interv 2002;57:283-97. doi: 10.1002/ccd.10323.
7. Sharp AJ, Patel N, Reeves BC, Angelini GD, Fiorentino F. Pharmacological interventions for the prevention of contrast-induced acute kidney injury in high-risk adult patients undergoing coronary angiography: A systematic review and meta-analysis of randomized controlled trials. Open Heart. 2019;6:e000864. doi: 10.1136/openhrt-2018-000864.
8. Li JX, Jin EZ, Yu LH, Li Y, Liu NN, Dong YM, et al. Oral N-acetylcysteine for prophylaxis of contrast-induced nephropathy in patients following coronary angioplasty: A meta-analysis. Exp Ther Med. 2017;14:1568-76. doi: 10.3892/etm.2017.4678.
9. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097. doi: 10.1371/journal.pmed.1000097.
10. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25:603-5. doi: 10.1007/s10654-010-9491-z.
11. Ala S, Moheisen A, Tahtian S, Hengli Z, Hendouie N. The Study of the Efficacy of N-Acetylcysteine for the Prevention of Contrast Induced Nephropathy in Normal Renal Functioning Patients Undergoing Corangiography. J Mazandaran Univ Med Sci. 2007;17:102-107.
12. Vallero A, Cesano G, Pozzato M, Garbo R, Minelli M, Quarello F, et al. Nefropatia da contrasto in cardiologia interventistica: assenza di vantaggi con impiego profilattico di N-Acetilcisteina [Contrast nephropathy in cardiac procedures: no advantages with prophylactic use of N-acetylcysteine (NAC)]. G Ital Nefrol. 2002;19:529-33.
13. Oldmeyer JB, Biddle WP, Wurderman RL, Moos AN, Cichowski E, Hillman DE. Acetylcysteine in the prevention of contrast-induced nephropathy after coronary angiography. Am Heart J. 2003;146:E23. doi: 10.1016/S0002-8703(03)00511-8.
14. Hoffmann U, Fischereder M, Krüger B, Drobnik W, Krämer BK. The Value of N-Acetylcysteine in the Prevention of Radiocontrast Agent-Induced Nephropathy Seems Questionable. J Am Soc Nephrol. 2004;15:407-10. doi: 10.1097/01.asn.0000080178.14856.55.
15. Hobiokoglu GF, Norguz T, Aksu H, Ozier O, Sari I, Karabulut A, et al. The effectiveness of oral N-acetylcysteine administered three hours before angiography in the prevention of contrast nephropathy in patients with mildly elevated creatinine levels. Turk Kardiyol Dern Arş. 2007;35:9-12.
16. Fung J Wu, Szeto CC, Chan WW, Kum LC, Chan AK, Wong JT, et al. Effect of N-acetylcysteine for prevention of contrast nephropathy in patients with moderate to severe renal insufficiency: a randomized trial. Am J Kidney Dis. 2004;43:801-8. doi: 10.1053/ajkd.2004.01.010.
17. Durham JD, Caputo C, Dukko S, Zaharakis S, Pahlavan M, Kelt J, et al. A randomized controlled trial of N-acetylcysteine to prevent contrast nephropathy in cardiac angiography. Kidney Int. 2002;62:2202-7. doi: 10.1046/j.1523-1755.2002.00671.x.
18. Baldrarreco DM, Verdu MB, Ramacciatte CF, Cremona LA, Lemos PA, Orías M, et al. Renoprotective effect of high periprocedural doses of oral N-acetylcysteine in patients scheduled to undergo a same-day angiography. Rev Fac Cien Med Univ Nac Cordoba. 2004;61:13-9.
19. Hsu CH, Lee JD, Lo PH, Lin JJ, Chang HW, Chou HT. Prevention of radiocontrast-induced nephropathy with N-acetylcysteine after cardiac angiography in diabetic patients with renal dysfunction, Mid Taiwan J Med. 2007;12:173-83.
20. Ozcan ES, Guneri S, Akdeniz B, Akyildiz IZ, Senaslan O, Bari N, et al. Sodium bicarbonate, N-acetylcysteine, and saline for prevention of radiocontrast-induced nephropathy. A comparison of 3 regimens for protecting contrast-induced nephropathy in patients undergoing coronary procedures. A single-center prospective controlled trial. Am Heart J. 2007;154:539-44. doi: 10.1016/j.ahj.2007.05.012.
21. Shavit L, Lifschitz M, Lachish T, Rosenmann D, Balkin J, Slotki I. Use of N-acetylcysteine prior to cardiac catheterization to prevent acute renal injury in patients with stage III chronic kidney disease. Harefuah. 2007;146:655-9.
22. Negita K, Miura T, Katsumi A, Tamai H, Takemoto K, Watarai M. Protective effect orally administered N-acetylcysteine on Contrast media-induced nephropathy: evaluation in acute and chronic phases. Jpn J Interv Cardiol. 2008;23:460-4.
nephropathy after cardiac catheterization in patients with diabetes mellitus and chronic kidney disease: A randomized clinical trial. Trials. 2009;10:43. doi: 10.1186/1745-6215-10-45.

24. Jo SH, Koo BK, Park JS, Kang HJ, Kim YJ, Kim HL, et al. N-acetylcysteine versus ASCorbic acid for Preventing contrast-induced nephropathy in patients with renal insufficiency undergoing coronary angiography. NASPI study-a prospective randomized controlled trial. Ame Heart J. 2009;157:576-83. doi: 10.1016/j.ahj.2008.11.010.

25. Buyukhatipoglu H, Sezen Y, Yildiz A, Bas M, Kirhan I, Ulas T, et al. N-acetylcysteine fails to prevent renal dysfunction and oxidative stress after nononidine contrast media administration during percutaneous coronary interventions. Pol Arch Med Wewn. 2010;120:383-9.

26. Calabrò P, Bianchi R, Caprile M, Sordelli C, Cappelli Bigazzi M, Palmieri R, et al. Use and efficacy of saline hydration and N-acetyl cysteine to prevent contrast-induced nephropathy in different populations of patients at high and low risk undergoing coronary artery angiography. Minerva Cardioangiol. 2010;58:35-40.

27. Kinbara T, Hayano T, Ohtani N, Furutani Y, Moritani K, Matsuzaki M. Efficacy of N-acetylcysteine and aminophylline in preventing contrast-induced nephropathy. J Cardiol. 2010;55:174-9.

28. Calabrò P, Bianchi R, Crisci M, Caprile M, Bigazzi MC, Palmieri R, et al. Use and efficacy of saline hydration and N-acetyl cysteine to prevent contrast-induced nephropathy in low-risk populations undergoing coronary artery angiography. Intern Emerg Med. 2011;6:503-7. doi: 10.1007/s11739-011-0513-y.

29. Khatami MR, Nikravan N, Salarfar M, Poorhosseini HR, Sadeghian S, Haj-Zeinali AM, et al. Comparison of Oral and Intravenous N-acetyl Cysteine in Preventing Contrast Nephropathy. Indian J Nephrol. 2020;30:403-8. doi: 10.4103/ijn.IJN_260_19.

30. Aslanger E, Uslu B, Akdeniz C, Polat N, Cizigici Y, Olflaz H. Intraprenal application of N-acetylcysteine for the prevention of contrast medium-induced nephropathy in primary angioplasty. Coron Artery Dis. 2012;23:265-70. doi: 10.1097/MCA.0b013e328351aacc.

31. Hsu TF, Huang MK, Yu SH, Yen DH, Kao WF, Chen YC, et al. N-acetylcysteine for the prevention of contrast-induced nephropathy in the emergency department. Intern Med. 2012;51:2709-14. doi: 10.2169/internalmedicine.51.7894.

32. Jaffery Z, Verma A, White CJ, Grant AG, Collins TJ, Grise MA, et al. A randomized trial of intravenous n-acetylcysteine to prevent contrast induced nephropathy in acute coronary syndromes. Catheter Cardiovasc Interv. 2012;79:921-6. doi: 10.1002/ccd.23157.

33. Alabtbaein MA, Almasood A, Alshurafah H, Alamri H, Tamim H. Efficacy of ascorbic acid, N-acetylcysteine, or combination of both on top of saline hydration versus saline hydration alone on prevention of contrast-induced nephropathy: a prospective randomized study. J Interv Cardiol. 2013;26:90-6. doi: 10.1111/j.1540-8183.2012.00767.x.

34. Alessandri N, Lanzi L, Garante CM, Tersigni F, Sergiacomi R, Petrassi M, et al. Prevention of acute renal failure post-contrast imaging in cardiology: a randomized study. Eur Rev Med Pharmacol Sci. 2013;17 Suppl 1:13-21.

35. Alioglu E, Saygi S, Turk U, Kirilmaz B, Tuzun N, Duman C, et al. N-Acetylcysteine in Preventing Contrast-Induced Nephropathy Assessed by Cystatin C. Cardiovasc Ther. 2013;31:168-73. doi: 10.1111/j.1755-5922.2011.00309.x.

36. Heguïlen RM, Liste AA, Payaslian M, Ortemberg MG, Albaracin LM, Bernasconi AR. N-acetyl-cysteine reduces the occurrence of contrast-induced acute kidney injury in patients with renal dysfunction: A single-center randomized controlled trial. Clinical and Experimental Nephrology. 2013;17:396-404. doi: 10.1007/s10157-012-0722-3.

37. Thaysen P, Lassen JF, Jensen SE, Hansen KN, Hansen HS, Christiansen EH, et al. Prevention of contrast-induced nephropathy with N-acetylcysteine or sodium bicarbonate in patients with ST-segment-myocardial infarction: a prospective, randomized, open-labeled trial. Circ Cardiovasc Interv. 2014;7:216-24. doi: 10.1161/circinterventions.113.000653.

38. Habib M, Hills A, Hammad A. N-acetylcysteine and/or ascorbic acid versus placebo to prevent contrast-induced nephropathy in patients undergoing elective cardiac catheterization: The NAPCIN trial; A single-center, prospective, randomized trial. Saudi J Kidney Dis Transpl. 2016;27:55-61. doi: 10.1016/j.sjkd.2015.09.014.

39. Biernacka-Fiałkowska B, Szukszut M, Suslik W, Dzierwa K, Tekieli Ł, Kostkiewicz M, et al. Intravenous N-acetylcysteine for the PRevention Of Contrast-induced nephropathy - a prospective, single-center, randomized, placebo-controlled trial. The INPROC trial. Postepy w Kardiologii Interwencyjnej. 2018;14:59-66. doi: 10.5114/aic.2018.74356.

40. Loomba RS, Shah PH, Aggarwal S, Arora RR. Role of N-Acetylcysteine to Prevent Contrast-Induced Nephropathy: A Meta-analysis. Am J Ther. 2016;23:e172-83. doi: 10.1097/MJT.0b013e31831b29dbc1.

41. Ali-Hassan-Sayegh S, Mirhosseini SJ, Ghodratipour Z, Sarrafan-Chaharsoughi Z, Rahimizadeh E, Karimi-Bondarabadi AA, et al. Strategies preventing contrast-induced nephropathy after coronary angiography: A comprehensive meta-analysis and systematic review of 125 randomized controlled trials. Angiology. 2017;68 :389-413. doi: 10.1177/0003319716661445.